CGTX
Cognition Therapeutics Inc
NASDAQ: CGTX · HEALTHCARE · BIOTECHNOLOGY
$1.26
+6.78% today
Updated 2026-04-30
Market cap
$114.37M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.32
Dividend yield
—
52W range
$0 – $4
Volume
1.2M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$3.50
+177.78%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-3.44M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $757000.00 | $-25.79M | $-33.97M | $-23.49M | $-3.34M |
| EPS | — | — | — | — | $-0.32 |
| Free cash flow | $-18.70M | $-16.16M | $-28.48M | $-24.59M | $-3.44M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Cognition Therapeutics Inc trades at $1.26. Our Smart Value Score of 20/100 indicates the stock is weak.
Frequently asked questions
What is Cognition Therapeutics Inc's stock price?
Cognition Therapeutics Inc (CGTX) trades at $1.26.
Is Cognition Therapeutics Inc overvalued?
Smart Value Score 20/100 (Grade F, Strong Sell).
What is the price target of Cognition Therapeutics Inc (CGTX)?
The analyst target price is $3.50, representing +177.8% upside from the current price of $1.26.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-88.60%
Beta1.40
50D MA$1.04
200D MA$1.39
Shares out0.09B
Float0.08B
Short ratio—
Avg volume1.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—